Niagen Bioscience (NAGE)
Builds Niagen-based supplements, ingredients, and clinical NAD+ channels.
Something off on this page? Send us feedback.
Sells Tru Niagen supplements, Niagen ingredients, and prescription-channel Niagen access. The current business is concentrated around NAD+ science after exiting the legacy reference-standards operation.
Built around Niagen, a proprietary nicotinamide riboside ingredient used to support NAD+ biology. The main commercial lines are Tru Niagen supplements, food-grade Niagen supplied to product makers, and pharmaceutical-grade Niagen supplied into prescription and compounding channels.
Sales are concentrated in consumer supplements and ingredient supply, with international distribution through partners and online channels. Pharmaceutical work remains a development activity rather than a commercial drug franchise.
Current execution depends on scientific credibility, patent protection, supplement and compounding regulation, product labeling discipline, and continued demand for Tru Niagen after the reference-standards divestiture.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | Roth Capital | Reiterate | Rating: —Target: — | Target: $10 |
| May 11, 2026 | H.C. Wainwright | Target | Target: — | Target: $11 |
| May 5, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $14 | Target: $10 |
| Nov 5, 2025 | Canaccord Genuity | Reiterate | Rating: —Target: — | Target: $14 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $66.7M · Total debt $2.3M · Total assets $106.6M · Shareholders' equity $82.5M
- Revenue
- $29.8M
- Operating income
- $700.0K
- Net income
- $963.0K
No dividends on record.
| Insiders | 1.35% | 1.08M shares | |
|---|---|---|---|
| 3 holders · as of Jul 8, 2026 | |||
| Other | 98.65% | 78.57M shares | |
| remainder | |||
79.64M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Robert N. FriedInsiderdirector, officer: Chief Executive Officer | 1.33% | 1.06M | filed Jul 8, 2026 |
Ozan PamirInsiderofficer: Chief Financial Officer | 0.02% | 13,848 | filed Jul 8, 2026 |
Carlos Luis LopezInsiderofficer: SVP, General Counsel | 0.01% | 4,565 | filed Jul 8, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 14, 2025 | Ozan Pamir | officer: Chief Financial Officer | +6,685 | $6.82 |
- Nature's Sunshine Products
Natural supplement peer with broad wellness-product overlap.
- USANA Health Sciences
Science-positioned nutrition and wellness supplement competitor.
- Nu Skin
Beauty-and-wellness seller with Pharmanex supplement overlap.
- Herbalife
Global nutrition platform competing for supplement and wellness spend.
- LifeVantage
Nutrigenomics supplement peer with aging and activation claims.
- Medifast
OPTAVIA wellness platform competing for guided health spend.
- Balchem
B2B nutrition-ingredient supplier competing with Niagen ingredients.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Niagen Bioscience | $3.08 | −0.49% | $246.1M | 16.6 | 27.5 | 1.9 | −4.3% |
| Nature's Sunshine Products | $12.96 | −1.97% | $232.5M | 13.1 | 12.1 | 0.5 | +2.0% |
| USANA Health Sciences | $14.15 | −4.26% | $272.9M | — | 13.9 | 0.3 | −5.3% |
| Nu Skin | $4.70 | −3.40% | $236.0M | — | 4.9 | 0.2 | −17.1% |
| Herbalife | $12.00 | −1.88% | $1.27B | 7.9 | 4.5 | 0.2 | +5.4% |
| LifeVantage | $6.10 | −1.93% | $78.5M | 15.5 | 21.0 | 0.4 | −23.1% |
| Medifast | $12.05 | −0.25% | $134.3M | — | — | 0.4 | −27.6% |
| Balchem | $168.76 | +0.21% | $5.41B | 33.1 | 30.4 | 5.0 | +11.2% |
| Median | 14.3 | 13.0 | 0.4 | −5.3% |